Condition: Esophageal Squamous Cell Carcinoma · Oligometastatic Disease · Radiotherapy · Sponsor: Fudan University
Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone. The primary end point was progression-free survival (PFS). The secondary end points included overall survival, side effects and local control.
This description comes directly from the study's public registry record.
Qi Liu, MD · 86-18017317882 · 18017317882@163.com
Kuaile Zhao, MD · 86-18017312534 · kuaile_z@sina.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai cancer center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06190782